Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays - An evaluation with samples from the PIOstat study

Clinical Laboratory

Volumn 55, Issue 7-8, 2009, Pages 275-281

  Pfützner, Andreas ^a,b   Efstrathios, Karagiannis ^c   Löbig, Mirjam ^a   Armbruster, Franz Paul ^d   Hanefeld, Markolf ^e   Forst, Thomas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c Takeda Pharma GmbH   (Germany)

^d IMMUNDIAGNOSTIK AG   (Germany)

^e Center for Clinical Research GWT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FATTY ACID OXIDATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SIMVASTATIN; THIAZOLIDINEDIONES;

EID: 70350536985     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 21: 160-178, 1998. (Pubitemid 28030404)
2. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 92: 141-146, 1993. (Pubitemid 23208989)
3. Austin MA, Edwards KL: Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 7: 167-171, 1996.
4. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260: 1917-1921, 1988.
5. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocr Metab 88: 4525-4532, 2003.
6. Van Gaal LF, Mertens L., De Block CE. Mechanisms linking obesity with cardiovascular disease, Nature 444: 875-880, 2006). (Pubitemid 46028447)
7. Forst T, Hohberg C, Pfützner A. Cardiovascular effects of disturbed insulin metabolism in metabolic syndrome and type 2 diabetes patients. Horm. Metab. Res. 41:123-131, 2009.
8. Torzewski M, Lackner KJ. Initiation and progression of atherosclerosis - enzymatic or oxidative modification of low-density lipoprotein?. Clin. Chem. Lab. Med. 44: 1389-1394, 2006.
9. Berliner JA, Heinicke JW. The role of oxidized lipoproteins in atherogenesis. Free Rad. Biol. Med. 20: 707-727, 1996.
10. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med. 2007 Feb; 120(2 Suppl 1): S3-8; Adipokine Review. (Pubitemid 46216205)
11. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 17: 319-326, 2007. (Pubitemid 46551691)
12. Hanefeld M. Posprandial hyperglycemia: noxious effects on the vessel wall. Int. J. Clin. Pract. Suppl. 129: 45-50, 2002.
13. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Köhler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 56: 491-496, 2007.
14. Hanefeld M, Marx N, Pfützner A, Baurecht W, Luebben G, Kargiannis E, Stier U, Forst T. Anti-Inflammatory Effect of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients with elevated High Sensitive CRP: The PIOSTAT study. J. Am. Coll. Cardiol. 49: 291-298, 2007.
15. Leonhardt W, Pfützner A, Müller I Pietzsch J, Forst T, Karagiannis E, Lübben G, Hanefeld M. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A subanalysis from the PIOSTAT study. Atherosclerosis. 201:155-162, 2008.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
17. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet.Med. 17: 299-307, 2000. (Pubitemid 30266125)
18. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126 1999.
19. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9: 471-474, 1998.
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density ipoprotein that increase its atherogenicity. N Engl J Med 320: 915-24, 1989. (Pubitemid 19101597)
21. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85: 1260-6, 1990. (Pubitemid 20123772)
22. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87: 5134-5138, 1990. (Pubitemid 20224287)
23. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 14:47-53, 199 ipoprotein 4.
24. Palinski W, Witztum JL. Immune responses to oxidative neo-epitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247: 371-380, 2000. (Pubitemid 30180039)
25. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J. Int. Med. 256: 413-420, 2004.
26. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J. 141: 957-963, 2001.
27. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother. 5: 2583-2596, 2004.
28. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi -Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standi E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schemthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366: 1279-1289, 2005.
29. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 49: 1772-1780, 2007. (Pubitemid 46629127)
30. Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, März W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 26: 2588-2594, 2003. (Pubitemid 37052104)